Spacecraft

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Ovarian cancer, Translocase, 5T4, Cell, NSCLC, Adenocarcinoma, Patient, Neoplasm, Immunoglobulin G, Cancer, Cancer research, Spacecraft, Translation, Abstract, AACR, ADC, Non-small-cell lung cancer, Vaccine

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Key Points: 
  • Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
  • The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models.
  • Tubulis is leveraging a proprietary suite of platform technologies to build a pipeline of uniquely matched ADC candidates that combine the right targeting molecule, conjugation chemistry and payload to deliver the true therapeutic value of the ADC approach.
  • The company’s lead candidates, both targeting solid tumor indications, are in late-stage preclinical testing, with TUB-040 ready for clinical evaluation.

Sierra Space Ghost Enters Flight Test Enabling Global Payload Delivery in 90 Minutes

Retrieved on: 
Monday, April 8, 2024
Aerospace, Technology, Manufacturing, Transport, Satellite, Military, Other Defense, Logistics, Supply Chain Management, Defense, Contracts, Engineering, Altitude, Freedom, Space Florida, Spacecraft, Architecture, Sierra Nevada Corporation, LLF, Multimedia, Sikorsky S-76, Orbital, Orbit, Communications satellite

(Photo: Sierra Space)

Key Points: 
  • (Photo: Sierra Space)
    This new technology propels Sierra Space into a new era of national security space and space logistics, promising to redefine the way critical defense supplies are delivered across the globe.
  • The Sierra Space Ghost Beta decelerator, part of the company’s recently announced Sierra Space Axelerator™ incubator , is a cutting-edge thermal protection system tailored for the safe return of small payloads from space.
  • Last month, the first drop test of the Sierra Space Ghost was completed in Florida, enabling Sierra Space test engineers to fully understand the flight characteristics of the system and how recovery operations can be rapidly completed on the ground.
  • “We envision having an inventory of Sierra Space Ghost vehicles strategically positioned and readily accessible and deployable within 90 minutes to critical locations anywhere on Earth.

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

Retrieved on: 
Tuesday, April 9, 2024
HCC, Malignancy, Disease, Lung, Patient, Bystander effect, Standard of care, Death, Spacecraft, IND, Investigational New Drug, Cancer, Drug resistance, Liver cancer, Therapy, ADC, Hepatocellular carcinoma, FDA, GPC3, Food, CDH3

SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.

Key Points: 
  • SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027.
  • BC2027, which is BioCity's second first-in-class antibody drug conjugate (ADC) approved for clinical development, targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells.
  • BC2027 binds with very high affinity to GPC3 and efficiently internalizes into cancer cells where it releases its cancer killing payload.
  • Dr. Yong Jiang Hei, CEO of BioCity, noted that "Drug resistance has increasingly become a challenge in cancer treatment.

Alif Semiconductor Announces World's First BLE and Matter Wireless Microcontroller to Feature Neural Co-Processor for AI/ML Workloads

Retrieved on: 
Tuesday, April 9, 2024
Cortex, Arm, LPA, BLE, Machine learning, Logic, LC3, Algorithm, DSP, HPA, WLCSP, Acceleration, Memory, Business, ARM Cortex-M, MCU, AI accelerator, Bluetooth Low Energy, Spacecraft, Senior, TWS, Architecture, Radio, DAC, NPU, TCM, GOPS, Family, MVE, Artificial intelligence, EEMBC, Lethargy, Video game

PLEASANTON, Calif., April 9, 2024 /PRNewswire/ -- Alif Semiconductor®, a leading global supplier of secure, connected, power efficient Artificial Intelligence and Machine Learning (AI/ML) microcontrollers (MCUs) and fusion processors, today announced the launch of the BallettoTM family, the world's first Bluetooth® Low Energy (BLE) wireless microcontroller to feature hardware optimization for AI/ML workloads.

Key Points: 
  • The Balletto family offers particularly strong performance in audio and sensor functions thanks to its excellent DSP and AI/ML capabilities and large on-die memory.
  • Neural network processing performance is up to 15x better than a Cortex-M4 processor can achieve.
  • Balletto includes the state-of-the-art multi-layered security fabric first introduced in Alif Semiconductors' Ensemble family of MCUs and fusion processors.
  • "Alif Semiconductor's Balletto family is targeting BLE challenges faced by the wireless audio and smart home industry today with a platform adapted to high bit-rate audio and the Matter ecosystem," said Reza Kazerounian, President and Co-Founder of Alif Semiconductor.

Alif Semiconductor Announces World's First BLE and Matter Wireless Microcontroller to Feature Neural Co-Processor for AI/ML Workloads

Retrieved on: 
Tuesday, April 9, 2024
Cortex, Arm, LPA, BLE, Machine learning, Logic, LC3, Algorithm, DSP, HPA, WLCSP, Acceleration, Memory, Business, ARM Cortex-M, MCU, AI accelerator, Bluetooth Low Energy, Spacecraft, Senior, TWS, Architecture, Radio, DAC, NPU, TCM, GOPS, Family, MVE, Artificial intelligence, EEMBC, Lethargy, Video game

PLEASANTON, Calif., April 9, 2024 /PRNewswire/ -- Alif Semiconductor®, a leading global supplier of secure, connected, power efficient Artificial Intelligence and Machine Learning (AI/ML) microcontrollers (MCUs) and fusion processors, today announced the launch of the BallettoTM family, the world's first Bluetooth® Low Energy (BLE) wireless microcontroller to feature hardware optimization for AI/ML workloads.

Key Points: 
  • The Balletto family offers particularly strong performance in audio and sensor functions thanks to its excellent DSP and AI/ML capabilities and large on-die memory.
  • Neural network processing performance is up to 15x better than a Cortex-M4 processor can achieve.
  • Balletto includes the state-of-the-art multi-layered security fabric first introduced in Alif Semiconductors' Ensemble family of MCUs and fusion processors.
  • "Alif Semiconductor's Balletto family is targeting BLE challenges faced by the wireless audio and smart home industry today with a platform adapted to high bit-rate audio and the Matter ecosystem," said Reza Kazerounian, President and Co-Founder of Alif Semiconductor.

Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer

Retrieved on: 
Tuesday, April 9, 2024
UBS, Biotechnology, CFO, Business, Patient, CBC, SAN, Cancer, Spacecraft, Pleasure, Wellesley College, Conjugation, Therapy, ADC, Antibody-drug conjugate, Management

SAN DIEGO and SHANGHAI, April 8, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).

Key Points: 
  • SAN DIEGO and SHANGHAI, April 8, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).
  • Ms. Jiang joins Adcentrx from CBC Group where she was Senior Managing Director and Management Committee Member.
  • "We are delighted to welcome Meng to Adcentrx's executive leadership team," said Hui Li, Ph.D., Founder and CEO of Adcentrx.
  • "We are glad to see Meng's continued contributions to Adcentrx as Chief Financial Officer," said Fu Wei, Chief Executive Officer at CBC Group.

Fleet Space Launches Next-Gen Centauri-6 Satellite on SpaceX's Bandwagon-1 Mission

Retrieved on: 
Monday, April 8, 2024
Lithium, LEO, SATCOM, SPIDER, Growth, Humanity, Entrepreneurship, PTT, History, 3D, Acquisition, Finniss Lithium Project, AI, Software, Falcon 9, Spacecraft, Moon, NASA, Rio Tinto, Kennedy Space Center, Centauri, Exosphere, SpaceX, Communications satellite

ADELAIDE, Australia, April 8, 2024 /PRNewswire/ -- Fleet Space Technologies, the leading Australian space exploration company, announced the successful deployment of its next-generation Centauri-6 satellite on SpaceX's Bandwagon-1 mission, launched aboard a SpaceX Falcon 9 from Launch Complex 39A at the Kennedy Space Center in Florida.

Key Points: 
  • ADELAIDE, Australia, April 8, 2024 /PRNewswire/ -- Fleet Space Technologies, the leading Australian space exploration company, announced the successful deployment of its next-generation Centauri-6 satellite on SpaceX's Bandwagon-1 mission, launched aboard a SpaceX Falcon 9 from Launch Complex 39A at the Kennedy Space Center in Florida.
  • The successful launch of Centauri-6 is the latest development from Fleet Space after a period of exponential growth and innovative breakthroughs unlocking new capabilities in the global space sector.
  • "Leveraging the latest advances in space technology, AI, and geophysics - Fleet Space is demonstrating a path to accelerate mineral exploration in a more data-driven, scalable, and sustainable way.
  • Centauri-6's design also leverages 3D-printed components - including the 3D-printed metal patch antenna Fleet Space pioneered on earlier Centauri satellites.

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024
ACT, Gene, Biotechnology, Acceleration, LOH, CDX, Risk, Patient, NGS, Biomarker, Research, MSI, DNA, Cancer, Spacecraft, AACR, MRD, Recurrence, FDA, Health, Plasma, Neoplasm, Medicine, Pharmaceutical industry

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

PredxBio Unveils Revolutionary SpaceIQ™ Platform Ushering in a New Era of Spatial Multi-Omics at 2024 AACR Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Diagnosis, Health informatics, Informatics, Immunotherapy, Disease, Patient, SAN, Head, Research, Tumor microenvironment, Cancer, AI, University, Doctor of Philosophy, Spacecraft, Proteomics, AACR, Ecosystem, Therapy, Health, Medical imaging

SAN DIEGO, April 7, 2024 /PRNewswire-PRWeb/ -- PredxBio, a leading technology company for spatial biology solutions, is set to make waves at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, taking place from April 7th to 11th. Attendees are invited to explore PredxBio Booth #952, where PredxBio will unveil its groundbreaking SpaceIQ™ platform, poised to redefine cancer research and patient care. In addition to the SpaceIQ platform, PredxBio will highlight its recent partnerships and growing ecosystem, demonstrating its commitment to collaborative innovation in cancer research and therapy development.

Key Points: 
  • Attendees are invited to explore PredxBio Booth #952, where PredxBio will unveil its groundbreaking SpaceIQ™ platform, poised to redefine cancer research and patient care.
  • SAN DIEGO, April 7, 2024 /PRNewswire-PRWeb/ -- PredxBio, a leading technology company for spatial biology solutions, is set to make waves at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, taking place from April 7th to 11th.
  • Attendees are invited to explore PredxBio Booth #952, where PredxBio will unveil its groundbreaking SpaceIQ™ platform, poised to redefine cancer research and patient care.
  • At the AACR Annual Meeting, PredxBio will showcase the latest innovations in unbiased spatial analytics and explainable AI with an immersive experience, offering live demonstrations of the SpaceIQ platform.

Shasqi to Present Data on Novel Tumor-Targeted Drug Activation Technology at 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 5, 2024
HER2, Toxicity, Therapeutic index, SAN, MMAE, Spacecraft, Abstract (summary), Nobel Prize, AACR, Neoplasm, Safety, Shasqi, Click chemistry, Pharmaceutical industry

SAN FRANCISCO, April 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.

Key Points: 
  • SAN FRANCISCO, April 5, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi"), a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced it will present five posters on the company's novel tumor-targeted drug activation approach at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, April 5-10, 2024.
  • The posters will describe data generated with Shasqi's CAPAC® (Click Activated Protodrugs Against Cancer) approach.
  • Shasqi is advancing a pipeline of assets based on validated targets and payloads.
  • The posters presented at the AACR meeting will show preclinical efficacy and safety data for assets targeting HER2, TROP2, and NECTIN-4, each paired with either an MMAE or exatecan payload.